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Abstract 
Multiple Sclerosis (MS) is a common cause of neurological disability among young adults and 
has a high economic burden. Currently there are 18 disease modifying agents for relapsing MS, 
which were tested in clinical trials versus placebo or an active comparator in a pairwise manner. 
However, there is currently no consensus on the fundamental principles of treatment approach 
and initial therapy selection. These factors result in variable use of disease modifying therapies. 
Here we describe the study protocol for Determining the Effectiveness of earLy Intensive Versus 
Escalation approaches for the Treatment of Relapsing-remitting Multiple Sclerosis (DELIVER-
MS). The main objective of the study is to determine whether an early highly effective treatment 
approach, defined as use of one of four monoclonal antibodies as initial therapy, is more 
effective than an escalation treatment approach (any other approved medication as initial 
therapy with subsequent escalation to higher efficacy treatments guided by radiological and 
clinical evaluation). The primary endpoint of the study is reduction in normalized brain volume 
loss from baseline visit to month 36 visit using MRI. Brain volume loss was selected as the best 
short-term predictor of long-term clinical disability. A total of 400 participants will be randomized 
1:1 using minimization to account for age and sex by site, and 400 will be enrolled into a parallel 
observational cohort. The study results will help guide overall treatment philosophy and will 
have important implications for patient choice, clinical practice, and treatment access.  
1. Introduction  
Multiple sclerosis (MS) affects approximately 1 million people in the United States (US) and is a 
common cause of disability in young adults. [1], [2]. MS has a high economic burden with a 
lifetime cost of approximately $4 million per patient with a significant portion attributable to 
medication costs [3], making comparative effectiveness research in MS important. Relapsing 
remitting MS (RRMS) is the most common form of the disease and is clinically characterized by 
discrete episodes of neurological impairment (relapses), which have an acute and unpredictable 
onset [4]. Relapses are the result of development of focal areas of inflammatory demyelination 
within the central nervous system (CNS). Relapse rate and degree of recovery after relapses 
predict long-term disability [5]. Significant advances have been made with development of 
immunomodulatory disease modifying therapies (DMTs), which may prevent the accrual of 
disability through reduction of new lesion formation and prevention of relapses. In the US, there 
are over a dozen DMT compounds approved to treat relapsing forms of MS; however, their 
efficacy to suppress relapses varies (Table 1), and differences in the tolerability and 
convenience of DMTs, in particular the complex safety profiles of the most effective DMTs, adds 
challenges to decision-making. There is little information on how different treatment algorithms 
affect long-term outcomes, and initial DMT choice is highly variable.  
<<TABLE 1 APPROXIMATELY HERE>> 
The comparative effectiveness and long-term benefits of MS DMTs are currently unknown. 
Patients newly diagnosed with RRMS and neurologists are currently faced with the dilemma of 
adopting one of two treatment approaches: 
• An “escalation” approach: starting therapy with a DMT that is considered safe but with a 
modest likelihood to control the patient's MS activity, and escalating to more potent 
therapies in the face of continued disease activity. 
• An early highly effective treatment (EHT) approach, in contrast, involves giving a high-
efficacy drug first-line, with greater likelihood of disease control but also rare potential for 
significant adverse effects. 
There is a paucity of studies examining the initial choice of DMTs in RRMS. Comparing 
individual therapies pairwise is cost-prohibitive and the anticipated approval of new MS 
medications (not available at the time of trial initiation), decreases the overall impact of such 
studies. The determination of comparative efficacy across approved treatments is inherently 
difficult; however, examining overall treatment strategies is feasible in a randomized design and 
could provide results that are broadly applicable. Therefore, Determining the Effectiveness of 
earLy Intensive Versus Escalation approaches for the Treatment of Relapsing-remitting Multiple 
Sclerosis (DELIVER-MS) seeks to study two different general treatment algorithms, an 
escalation approach versus an EHT approach, both commonly used in MS but that differ 
considerably in underlying philosophy. By comparing the effectiveness of two general DMT 
algorithms, we anticipate results that will be widely applicable to current and future DMTs. 
2. Methods  
2.1 Study Design 
DELIVER-MS is a multicenter pragmatic parallel group, open label, rater blinded, randomized 
clinical trial. 400 participants will be randomized in a 1:1 ratio to an EHT approach as initial 
therapy after diagnosis (alemtuzumab, natalizumab, rituximab, or ocrelizumab at clinician and 
participant discretion), or escalation approach (any approved DMT except alemtuzumab, 
natalizumab, rituximab, or ocrelizumab as initial therapy with subsequent escalation to any 
approved DMT as indicated). The study is conducted across 24 sites in the United Kingdom 
(UK) and US. All treatments used are in accordance with local practice and DMT costs are 
covered within regular clinical practice. Only Food and Drug Administration (FDA)/National 
Health Services (NHS) approved therapies are used, with the exception of rituximab, for which 
an investigational new drug exemption was granted given the frequent off-label use of this 
medication in clinical practice in the US.  Study visits include clinical assessments, cognitive 
testing, MRI, and patient reported outcome measures (PROMs) at Baseline, 12 months, 24 
months, and 36 months.  
400 participants total will be recruited for the randomized controlled trial (RCT). Up to 400 
additional participants unable to obtain coverage for a medication in their randomized arm or not 
agreeable to randomization will be recruited for an observational cohort, which includes an 
identical assessment schedule as the RCT, without randomization. The recruitment flow 
diagram is presented in Figure 1. The study steering committee and study advisory committee 
comprised of investigators, patients, patient advocacy agencies, and third-party payer 
representatives developed and finalized the study protocol [20]. 
2.2 Eligibility Criteria and Study Screening 
To be eligible for the study, participants must meet the following eligibility criteria at the 
screening visit: 1) men and women between 18 to 60 years of age, 2) established diagnosis of 
MS, as defined by the 2017 revision of McDonald Diagnostic Criteria [21], 3) RRMS disease 
course as defined by the 2013 revisions of the MS clinical course definition [22], 4) evidence of 
active disease based on: one or more MS relapses within the last 18 months prior to screening 
visit or radiological evidence of MS activity (≥2 new T2 lesions within the last 12 months from 
screening [compared to a previous recent MRI within 18 months of screening] or ≥1 gadolinium 
enhancing lesion (GdE) demonstrated on brain or spinal cord MRI performed within the last 12 
months of screening), 5) ambulatory with disease onset ≤ 5 years and treatment-naïve (i.e., no 
MS DMT at any time in the past), 6) eligible to receive at least one form of DMT within each 
treatment arm and 7) Expanded Disability Status Scale (EDSS) at Baseline visit ≤ 6.5. 
Exclusion criteria include 1) contraindications to all forms of DMT in either of the treatment 
arms, 2) prior treatment with any of the following medications: natalizumab, alemtuzumab, 
ocrelizumab, rituximab, cladribine, interferon beta- 1a, interferon beta-1b, pegylated interferon 
beta-1a, glatiramer acetate, fingolimod, teriflunomide, dimethyl fumarate, daclizumab, 
mitoxantrone, 3) treatment with any of the following medications for reasons other than MS, in 
the last 12 months: cyclophosphamide, azathioprine, mycophenolate mofetil, cyclosporine, 
methotrexate, leflunomide, laquinimod, atacicept, other monoclonal antibodies, 4) clinically 
relevant medical or surgical conditions that, in the opinion of the investigator, would put the 
subject at risk by participating in the study, 5) inability to provide informed consent, 6) 
contraindication or inability to undergo MRI with Gd due to metal or metal implants, allergy to Gd 
contrast, claustrophobia, pain, spasticity, or excessive movement related to tremor, 7) 
unwillingness or inability to comply with the requirements of this protocol including the presence 
of any condition (physical, mental, or social) that, in the opinion of the investigator, is likely to 
affect the participant's ability to comply with the study protocol. 
After providing written informed consent, participants complete screening procedures to confirm 
eligibility. After screening assessments are complete and all eligibility criteria is confirmed, 
participants are formally enrolled into the study.  
2.3 Study Treatments 
Early Highly Effective treatment arm 
The EHT arm is one of the two randomized arms of the study and involves use of alemtuzumab, 
natalizumab, ocrelizumab, or rituximab as initial DMT. Once participants are randomized to the 
EHT arm, the choice of the specific DMT is made based on individual patient characteristics, by 
the patient, and the treating clinician in accordance with local guidelines. Participants starting 
EHT therapies may subsequently switch medications but are mostly expected to remain on 
these treatments for the duration of the study, based on described clinical experience [23–25]. 
Natalizumab treatment is used as described in prescribing information as 300 milligram (mg) 
intravenous infusion over one hour every four weeks. Alemtuzumab is used as approved as 12 
mg/day administered by intravenous infusion for 2 treatment courses: first treatment course 12 
mg/day on 5 consecutive days (60 mg total dose) and second treatment course 12 mg/day on 3 
consecutive days (36 mg total dose) administered 12 months after the first treatment course. 
Ocrelizumab is used as approved by regulatory agencies, 600 mg by intravenous infusion every 
24 weeks, administered as two 300 mg infusions on days 1 and 15 for the start dose and as a 
single 600 mg infusion thereafter. The regimen of rituximab includes two 1000 mg IV infusions 
separated by 2 weeks (one course) followed by 1000 mg every 6 months thereafter. In addition, 
lower doses of the medication can be used, both during the first treatment course and 
subsequent treatment courses including doses of 500 mg every 6 months or 1000 mg every 12 
months.  
Escalation Arm 
The escalation arm involves use of any approved MS DMT, other than those described in EHT, 
as initial therapy with or without subsequent switch to any other approved treatment. 
Maintenance dosages used for the different initial escalation approaches include: glatiramer 
acetate (20 mg daily or 40 mg three times per week by subcutaneous [SC] injection); interferon 
beta-1a (22 or 44 microgram [mcg] SC three times per week); interferon beta-1a (30 mcg 
weekly intramuscular injection); interferon beta-1b (0.25 mg SC every other day); peginterferon 
beta-1a (125 mcg SC every 14 days); fingolimod (0.5 mg daily orally); teriflunomide (7 or 14 mg 
once daily orally); dimethyl fumarate (240 mg by mouth twice daily); cladribine (40-100 mg orally 
per treatment course); siponimod (1-2 mg daily orally after titration). We anticipate some 
participants will change therapy due to clinical activity, MRI activity, side effects, or 
convenience. Participants are allowed to switch, after receiving the initial dose, to any other 
approved therapies listed above at the discretion of the participant or the neurologist and in 
addition may escalate to natalizumab, alemtuzumab, rituximab, ocrelizumab (at doses listed 
above), or mitoxantrone (12 mg/m2 every 3 months IV, with cumulative dose limits and prior 
cardiac evaluation) per label indications. As new therapies become available, the steering 
committee will assign them to the EHT or escalation arm options. 
Randomization 
Patients will be randomized to the escalation or EHT arm 1:1 using minimisation. In 
minimisation the aim to minimize the imbalance between the number of patients in each 
treatment arm over multiple stratification variables. In DELIVER-MS minimisation will balance 
age and sex by site. Age will be grouped by tertiles (18-30, 31-36, 37-60) based on a normal 
distribution. Randomization using minimisation will be implemented via a web based system by 
a commercial provider, eResearch Technology Incorporated (ERT). 
Observational Cohort 
The emphasis of the study is to conduct a pragmatic randomized trial. Preparatory data 
collected for the DELIVER-MS study, previously published [20], indicated that a sizeable 
proportion of individuals would not be willing to be randomized. To provide additional data 
regarding the primary research question, participants who do not agree to randomization, or 
who agree to randomization but are not approved by insurance for coverage for a medication in 
the arm to which they were randomized despite appeal, are invited to participate in the 
observational cohort of the study. Participants in the observational study can use any treatment 
in the EHT or escalation arm at the discretion of the participant and treating clinicians. 
Participants may enroll directly into the observational cohort (excluding those who enter after 
randomization). In order to achieve balance between randomized and observational study 
components, sites are asked that the number of participants enrolled in the RCT should equal or 
exceed that in the observational study at all times. The observational cohort has the same 
assessments as the randomized arms, both in terms of MRI and clinical testing. The goal of 
including an observational cohort is to ensure information on participants not willing to 
randomize or unable to start randomized medication is still collected and analyzed. The analysis 
in the observational study will focus on efficacy measures after minimizing treatment selection 
bias. 
2.4 Study Schedule and Outcomes 
Study visits include Screening (SC), Baseline (BL), and Months 6, 12, 24, and 36 visits. The full 
study schedule is presented in Table 2.  
Windows for study visits include +/- 45 days, with the exception of the baseline visit, which will 
occur as close as possible prior to DMT start, after insurance approval of medication, and within 
90 days of the screening visit. If the prospective participant has not initiated the prescribed 
medication by 90 days post-randomization, they are withdrawn from the study, unless prior 
approval from the study administrative team has been obtained, and would not be allowed to be 
re-screened for the study. Telephone calls are conducted at Months 3, 9, 15, 18, 21, 27, 30, and 
33 +/-15 days.  
<<TABLE 2 APPROXIMATELY HERE>> 
 
Medical history, MS history, current MS symptoms, and eligibility are reviewed at the Screening 
Visit. Following confirmation of eligibility, participants are randomized and subsequently 
scheduled for the Baseline Visit once DMT approval is obtained and approximate start date for 
medication is known. Interval history, Adverse Event (AE) review, disease therapy review, 
concomitant therapy review, relapse review, and laboratory testing are conducted at Baseline 
and Months 3, 6, 9, 12, 15, 18, 24, 27, 30, 33, and 36. Vital signs, EDSS, MS Functional 
Composite (MSFC)-4 and PROs are obtained at Baseline and Months 12, 24, 36.  
Brain MRI is obtained at Baseline (pre-treatment) and Months 6, 12, 24, and 36. The acquisition 
window for the baseline MRI is as close as possible prior to DMT start date and within 90 days 
of the screening visit. For scans other than baseline, the window for MRI is +/- 45 days of the 
clinical visit.  
A repository of biosamples from participants is collected. Participation in the repository is 
optional for all participants. The purpose of the biorepository is so that biomarker discovery 
studies can be conducted after full enrollment into the trial to evaluate for predictors of longer-
term disability and treatment response with the ultimate goal of individualizing treatment 
approaches in MS. Samples are collected at baseline and month 6 visits. Biosamples collected 
will include frozen serum, whole plasma for DNA, and peripheral blood mononuclear cells. 
Samples from US sites are shipped to, processed, and stored at the University of Alabama-
Birmingham MS Center, in Birmingham, Alabama, US. Samples from UK sites are stored at the 
Welsh Neuroscience Research Tissue Bank, in Cardiff, Wales, UK.  
2.5 Adverse event reporting 
Reporting of these AEs will be conducted by the regular clinical provider for each participant as 
occurs in clinical practice. Because the study employs medications that are already approved, 
reporting of non-serious AEs is not being conducted, and there is no formal data safety 
monitoring board. Serious AEs are and AEs leading to treatment discontinuation are recorded in 
the study chart at the time of study visits and telephone visits. No formal reporting procedure to 
the FDA or health regulatory agencies is conducted within the contexts of the study.  
Efficacy Assessments 
Brain MRI 
MRI is conducted using a predefined imaging protocol to include: localizer (<1 minute), 3D T1-
weighted pre-contrast image such as Magnetization-Prepared Rapid Acquisition of Gradient 
Echoes (MPRAGE) or Turbo Field Echo (TFE) with 1 mm isotropic resolution (approximately 5 
minutes acquisition time), 3D T2 Fluid-Attenuated Inversion Recovery (FLAIR) 1 mm isotropic 
resolution (approximately 6 minutes acquisition time), 2D T2-weighted short and long dual-echo 
with 3-4mm slice thickness (approximately 3 minutes acquisition time), post-contrast T1-
weighted image (approximately 5 minutes with delay). The type of Gd post contrast agent is at 
the discretion of the sites. The scan sequence was selected to be minimally complex, easy to 
acquire at all sites, and of short duration. MRI scanners and sequences are approved by the 
image analysis team at Cleveland Clinic. A dummy scan is completed at all sites prior to 
machine/sequence approval to troubleshoot any protocol problems.  
Images are reported by a local radiologist according to routine clinical care. Image analysis is 
performed centrally at the Cleveland MRI Image Analysis Center and includes determination of 
baseline fractional brain volume (Brain Parenchymal Fraction [BPF] method with longitudinal 
changes determined using the Jacobian Integration (JI) method [26–28]. Other MRI measures 
include: GdE lesions (number, volume), T2-hyperintense lesions (N/E lesions, volume), T1-
hypointense lesions (volume), and gray matter fraction. 
Clinician-assessed measures of neurologic disability 
The clinician-assessed measures of MS disease status listed below are used in this study at 
baseline and every 12 months including: 1) neurologic examination and calculation of functional 
system scales and EDSS, 2) MSFC-4 consisting of the Timed 25 foot walk [T25FW] (lower 
extremity function), 9 Hole Peg Test [9HPT] (upper extremity function), Symbol Digit Modalities 
Test [SDMT] (cognitive processing speed), and low contrast letter acuity (visual function). 
Relapse data (onset, duration, symptoms, and use of steroids) are captured at study visits 
retrospectively. Participants do not have unscheduled study visits to evaluate for potential 
relapses, as this was not the primary study outcome.  
Patient-reported outcomes 
The PROMs listed below are used in this study and are assessed at baseline and every 12 
months: Multiple Sclerosis Impact Scale 29 (MSIS-29) [29], Patient Health Questionnaire (PHQ-
8) [30], Neurological Quality of Life Scale (Neuro-QoL) short forms [31], and Treatment 
Satisfaction Questionnaire for Medication (TSQM) [32]. Treatment adherence and satisfaction 
are measured in addition to TSQM at Baseline and every 3 months with reports of percentage 
medication taken as scheduled.  
3. Statistical Methods 
3.1 Sample size calculation 
The sample size was calculated based on the primary outcome measure of brain volume 
change, under the null hypothesis that escalation and EHT arms do not differ in relation to brain 
volume loss over the study period. Using published data from phase III trials published at the 
time of study design, we extracted a yearly brain volume change for each therapy. We then 
calculated yearly averages of brain volume loss for EHT treatments (natalizumab, 
alemtuzumab, rituximab, ocrelizumab), oral treatments (fingolimod, teriflunomide, dimethyl 
fumarate) and injectables (glatiramer, interferons). We used a standard deviation of 0.53, based 
on our image analysis laboratory’s estimate incorporating clinical trial data and modern brain 
volume estimation techniques. We modeled the effect size for the EHT arm by using the EHT 
average over 3 years. For the escalation arm we modeled the first 2 years of treatment as 50% 
of participants using oral agents and 50% of patients using injectable agents. We modeled the 
third year of treatment as 60% of participants continuing with oral/injectable agents, and 40% 
escalating to EHT therapies (using the average effect of natalizumab, alemtuzumab, rituximab, 
ocrelizumab). This modeling was based on current US and UK practice for first-line therapies 
and an estimated 30% escalation rate to highly effective therapies (for a more conservative 
sample size estimate, we used a 40% escalation in the third year of treatment). This resulted in 
an estimated annual brain volume loss of 0.442 in the escalation arm, and 0.282 in the EHT 
arm, over the course of 3 years.  
Using the above estimated effects we conducted a sample size calculation based on a two 
sided t-test, a common standard deviation assumed to be 0.53 per year (based on the 
laquinimod versus interferon beta-1a vs. placebo study using JI), 80% power, and a 5% 
significance level. This requires 180 participants per group. Should 10% of participants drop out 
of the study or become lost to follow-up, 200 participants per group would be required.  
3.2 Primary outcome analysis 
The aim of this study is to test the effectiveness of EHT versus escalation treatment approaches 
with a primary outcome of brain volume loss from the baseline to Month 36. Analysis will be 
performed using a linear regression model, adjusting for treatment arm, age, sex, and baseline 
brain volume. The main result will be presented as the mean difference between treatment arms 
in the annualized percentage brain volume loss, along with a 95% confidence interval.  
Brain volume loss as a short term outcome  
Brain volume loss over three years was selected as the primary outcome for the study because 
it is meaningful to patients (as demonstrated in preparatory focus groups),[20] is feasible to be 
conducted in a 3-year multicenter study, and is the currently available measure most predictive 
of future MS-related disability. Volume loss shows good correlations with physical disability over 
both the short term[33] and long-term (Table 3). Brain volume loss also correlates with loss of 
cognitive function, an important feature of long-term disability in MS as well as with fatigue. 
Several studies have found that brain volume loss correlates cross-sectionally with cognitive 
measures including processing speed [34,35], verbal memory[36,37], and short term 
memory[38]. Brain volume also is predictive of future cognitive function, as well [39,40]. Physical 
and cognitive fatigue are associated with brain volume loss [41,42]. Brain volume loss 
represents a meaningful and predictive outcome measure that is ideal as a global measure to 
compare DMT approaches. Brain volume loss rates across clinical trials are presented in Table 
4. 
<<TABLE 3-4 APPROXIMATELY HERE>> 
3.3 Secondary outcome analysis 
MRI secondary outcomes include 6 month to 36 month change in brain volume to account for 
pseudoatrophy effects. The main clinical secondary endpoint is the proportion of subjects with 
worsening on a multidimensional composite comprised of EDSS increase (>1.0 point or 1.5 
points for those with EDSS of 0 at Baseline), 20% increase in T25FW, 20% increase in 9HPT, 
10% decrease in SDMT, or 1-line decrease in LCLA confirmed over 12 months. This endpoint 
will be analyzed using a logistic regression model adjusting for treatment arm, age and sex. The 
results of our analyses will be adjusted odds ratios and 95% confidence intervals that indicate 
the effect of EHT vs. escalation arm on the outcome of interest. Baseline to Month 36 changes 
in the MSIS-29 and Neuro-QoL, the main secondary endpoint for PROs, will be analyzed using 
linear regression as described for the primary outcome. The secondary outcome regarding 
safety is a comparison of SAEs across the two treatment groups. This will be assessed in two 
ways. First, the percentage of participants who experience any SAE in each group will be 
compared using a chi-square test. Then, the rates of SAEs in each group will be compared 
using Poisson regressions. We also will compare the percentage of subjects with any SAE, 
CTCAE grade 3 and 4 AE, and AEs that lead to treatment discontinuation. Analysis will focus on 
all SAEs with a secondary analysis of treatment-related SAEs. Cumulative response of the 
TSQM pertaining to side-effects will be compared between EHT and escalation arms as well as 
individual therapies.  
3.4 Exploratory outcome analyses 
Additional exploratory outcomes include assessment of brain volume loss from Baseline to 
Month 12, Months 12 to 24, Months 12 to 36, and Months 24 to 36. This analysis will be 
conducted in a similar fashion to the primary outcome. We will also compare changes in T2 
lesions volume, T1 hypointense lesion volume, and gray matter fraction using the same time 
points and analogous analyses.  
3.5 Advisory Committee and Patient Engagement 
An advisory committee was formed with stakeholders including people with MS, caregivers of 
people with MS, insurance industry representatives, health care agency regulators, advocacy 
group representatives (National Multiple Sclerosis Society, UK Multiple Sclerosis Society), and 
investigators. The advisory committee informs and guides the planning, conducting, and 
dissemination of the clinical trial. The advisory committee works closely with the steering 
committee (shared members from both committees) so that the advisory position strongly 
affects all study-related decisions.  
4. Discussion  
The DELIVER MS study seeks to answer an important question regarding the optimal approach 
to DMT use in early RRMS. MS is a common disease causing significant disability in young 
adults for which treatments are only partially effective. The study seeks to determine whether an 
EHT approach to DMT is more efficacious in preventing brain volume loss than an escalation 
approach. It is anticipated that results of the study will inform treatment decisions for MS 
patients. All participants will receive approved DMTs and, after the initial dose, will be allowed to 
change therapies (according to their licensed indication) at the discretion of the clinical 
neurologists and participants.  
MS is a disease that starts as an inflammatory process in which immune cells infiltrate the CNS 
and destroy the myelin sheath surrounding neuronal cells. This demyelination, and the resulting 
neuroaxonal loss, is responsible for the physical symptoms of MS. The target of all MS DMT is 
by either decreasing the activity of the immune cells or by preventing them from infiltrating the 
CNS. The use of an escalation approach aims to maximize the safety of DMT. But this approach 
potentially puts patients at risk of incomplete control of disease activity, which may result in an 
increase in disability over time. The EHT approach aims to maximize efficacy early in the 
disease course but may have greater exposure to risk. The serious AEs associated with EHT 
DMTs occur in a small proportion of patients but may have high morbidity as illustrated with 
cases of progressive multifocal leukoencephalopathy, herpes infections, and atypical bacterial 
infections. However, several EHT options with a relatively safe profile do exist, including the use 
of natalizumab in JC virus seronegative patients, and the use of ocrelizumab or rituximab. The 
balance between the potential for DMT-associated AEs and the potential for disability 
accumulation as a result of incomplete disease control is a common discussion in the 
neurologist’s office. A randomized study may limit this flexibility, but by randomizing to an 
approach patients and neurologists retain the ability to make decisions on individual therapies 
within medication groups. The options provided in this study for switching therapies as needed 
at the discretion of the participant and neurologist makes the study similar to routine clinical 
practice. We also selected inclusion criteria that allowed patients with a minimum of relapse 
(relapse within the last 18 months) and inflammatory activity (new T2 lesions/ gadolinium 
enhancing lesions within the last 12 months) so the study population was similar to patients 
newly starting DMTs in clinical practice.  
There is currently no consensus on selection of initial DMTs. The comparative effectiveness and 
the long-term benefits of MS DMTs are currently unknown. We seek to study two different 
treatment algorithms, both commonly used in MS but that differ considerably. By comparing the 
efficacy of two generic DMT algorithms, escalation vs EHT, we anticipate results that will be 
widely applicable to persons with MS. Some observational data also support the early use of 
EHT over escalation approaches [58]. Brain volume was selected as the outcome at 36 months, 
but long term plans will be put into place to follow patients in extension studies with follow-up of 
5-10 years 
DELIVER-MS is an international clinical trial. We considered it important to have representation 
of more than one country as prescribing practices might vary between North America and 
Europe. Although some regulatory hurdles needed to be overcome for an international study, 
we considered the effort a good investment for wider application of study results.   
DELIVER-MS is also different to other MS DMT trials with both RCT and an observational study. 
The observational cohort is formed by participants not amenable to randomization, or who agree 
to randomization but are not approved for coverage for DMT coverage in the arm to which they 
were randomized, despite an appeal process. The observational cohort will be analyzed using 
propensity score adjustment based on baseline covariates with 1:1 matching adjustment. 
Although the RCT is the main study deliverable, the results of the observational arm and 
randomized arm will be compared and then the matched observational cohort and randomized 
cohort will be pooled for analysis. Further we will use a formal sensitivity analysis [59] to limit the 
degree of hidden bias that would be required to nullify significant conclusions from the matched 
analysis. We also note that the observational cohort is not a homogeneous sample and can be 
further divided for analyses into two subsamples as those participants eligible for the clinical trial 
who did not consent to randomization and those participants ineligible for the clinical trial due to 
lack of insurance approval. Therefore, we can perform appropriate pairwise comparisons of the 
three samples (clinical trial and two subsample observations cohorts) within each treatment arm 
on all outcomes of interest as well as appropriate pairwise comparisons of the three samples 
between treatment arms. Although the observational study will be informative to the population 
not randomized, inherent biases in observational studies and inability to correct for unmeasured 
confounders may still exist. 
We believe that the patient voice is crucial in reducing the unwarranted variation of MS 
treatment prescribing. Patient empowerment with educational approaches in conditions such as 
prostate cancer and benign prostatic hyperplasia has shown particular success in reducing 
unwarranted variation of prescribing. The current study will be conducted in adherence with 
engagement principles based on trust, respect, and transparency.[20] Patients with MS will be 
integral members of the research team and compensated for their time at fair market value. 
These patient partners will be involved in the planning, conduction, and results dissemination of 
the study. Training will be conducted in a bidirectional manner to ensure all team members 
improve both scientific knowledge and stakeholder perspectives. Bidirectional training includes 
training to the study investigators by stake holders and vice-versa. Training will ensure 
perspectives and rationale for all members of the advisory group are understood and 
addressed. During the study planning and execution, we will disseminate the current prescribing 
uncertainty to patients and their families. Our patient engagement team will liaise and 
coordinate their efforts with other stakeholders aiming to equip patients to ask more questions 
and to know more about what they might expect from their treatments.  
The findings of this study will have an immediate impact on the management of MS 
internationally. The results will inform overall treatment philosophy and will guide both patients 
and clinicians in their decision making process. The study results are expected to impact the 
payers (insurance) and government agencies that decide on medication coverage. 
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Table 1 Effect of approved disease modifying agents on relapse reduction rates and 
relative risks 
Name Route  Efficacy Major Risks/Side Effects 
Interferon Beta-
1a 
IM 32% reduction in Annual 
Relapse Rate (ARR) compared 
to placebo 6  
Flu-like side effects, injection 
site reactions, leukopenia, 




SC 34% reduction in ARR 
compared to placebo [7] 
Flu-like side effects, injection 
site reactions, leukopenia, 




SC 32% reduction in ARR 
compared to placebo 8  
Flu-like side effects, injection 
site reactions, leukopenia, 





SC 28% reduction in ARR 
compared to placebo 9  
Flu-like side effects, injection 
site reactions, leukopenia, 




SC 29% reduction in ARR 
compared to placebo 10  
Injection site reactions, 
immediate post-injection 
systemic reaction 
Fingolimod PO 54% reduction in ARR 
compared to placebo 11     
Cardiac events (bradycardia, 
atrio-ventricular block, cardiac 
arrest, arrhythmias), herpes 
infection, macular edema, 
elevated liver enzymes, 
lymphopenia 
Teriflunomide PO 31% reduction in ARR 
compared to placebo 12  
Teratogenesis, liver 
dysfunction, reactivation of 
latent tuberculosis, hair loss 
Dimethyl 
Fumarate 
PO 44-53% reduction in ARR 
compared to placebo13, 14 
Gastrointestinal symptoms 
(nausea, vomiting, abdominal 
pain, diarrhea), flushing, 
lymphopenia 
Daclizumab SC 54% reduction in ARR 
compared to placebo 15 
Skin reactions, liver 
dysfunction, depression, 
infections 
Cladribine PO 58% reduction in ARR 
compared to placebo 16 
Lymphopenia, herpes zoster, 
teratogenesis.  
Siponimod PO 55% reduction in ARR 
compared to placebo in 
secondary progressive MS 
(SPMS)17 
Lymphopenia, elevated liver 
enzymes, bradycardia, 
bradyarrhythmias), herpes 
infection, macular edema, 
seizures 
HIGHLY EFFECTIVE 
Natalizumab IV 68% reduction in ARR 
compared to placebo 18 
Infusion reactions, progressive 
multifocal 
leukoencephalopathy, 
lymphopenia, elevated liver 
enzymes, herpes simplex 
encephalitis 
Alemtuzumab IV 55% reduction in ARR 
compared to interferon beta-1a 
19 
Infusion reactions, infections, 
autoimmune 
thrombocytopenia. 
autoimmune thyroid disease, 
autoimmune kidney disease 
Ocrelizumab IV 47% reduction in ARR 





Intramuscular (IM), subcutaneous (SC), orally (PO), intravenous (IV)  
 
  
Table 2. Study Flow Chart  
Visit 
1 
Visit 2 Visit 3,5, 7-9, 11-
13 
Visit 4 Visits 6,10,14 
 
Procedures SC BL Telephone 
(Months 3, 9, 15, 








12, 24, 36) 
Early 
Withdrawal 
Informed consent X 
     
Eligibility criteria X 
     
Medical, MS history X 
     
Cohort Determination (RCT vs 
OBS) 
X 
     
Randomization X      
Interval history 
 
X X X X X 
Adverse Events review 
  
X X X X 
Disease therapy review 
  
X X X X 
Concomitant therapy review 
 
X X X X X 
Relapse review 
 
X X X X X 
Vital signs X X 
  
X X 
EDSS X X 
  
X X 
Multiple Sclerosis Functional 














X X X 
Lab testing review3 X X X X X X 
Biorepository blood sampling  X  X   
1 MSFC-4 (Timed 25-Foot Walk T25FW, 9-Hole Peg Test 9HPT, Symbol Digit Modalities Test SDMT, low 
contrast letter acuity (LCLA),2 Includes Multiple Sclerosis Impact Scale (MSIS-29), Patient Health Questionnaire 8 
items (PHQ-8), Treatment Satisfaction Questionnaire for Medication(TSQM), Quality of Life in Neurological 
Disorders (Neuro-QoL) short forms, 3May include recording of: complete blood count, metabolic panel, JC virus 
serology, Varicella zoster serology, interferon neutralizing antibodies, natalizumab neutralizing antibodies, 
rituximab neutralizing antibodies, immunoglobulin levels, CD19 counts, tuberculosis screening testing, thyroid 
function testing, urine analysis. 
 
  
Table 3 Studies Showing Brain Volume Loss as a Predictor of Physical Disability 




42, 2015 EDSS confirmed disability progression 
over 4 years 
3635  SIENA, SIENAX 
43, 2013 EDSS at 10 years 261 SIENA 
44, 2000 EDSS progression at 8 years 160 BPF 
45, 2010 Development of clinically definite MS 99 SIENA 
46, 2014 EDSS disease progression at 5/10 
years 
81 SIENA 
47, 2007 EDSS at 2 years 79 SIENA 
48, 2010 Increased EDSS at 5.5 years 54 SIENA 
49, 2003 EDSS over 4 years 38 Brain and lateral 
ventricle volumes 
50, 2012 EDSS disease progression at 7 years 27 SIENA 
 
BPF = brain parenchymal fraction, EDSS – Expanded Disability Status Scale, SIENA = Secure 
Information Exchange Network Application 
  
Figure 1: Flow chart for patients entering study 
 
Abbreviations: EHT: early highly effective therapy 
 
